The ALPINE trial shows improved outcomes with zanubrutinib versus ibrutinib in R/R CLL 

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the ALPINE trial (NCT03734016), comparing zanubrutinib to ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The trial demonstrated an improved overall response rate (ORR) and progression-free survival (PFS) in the zanubrutinib arm, especially in high-risk patients with 17p deletions. Dr Brown highlights that these positive results encourage clinicians to incorporate zanubrutinib into clinical practice. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.